GHRELIN ANTAGONISM IN APPETITE AND ADIPOSITY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 肥胖是2型糖尿病、心血管疾病和某些类型癌症等疾病的主要危险因素。大脑中的下丘脑是食物摄入的中央调节器，因此是抗肥胖药物的关键靶点。Ghrelin是一种外周激素，作用于下丘脑神经元以增加食物摄入。人体研究表明，注入生长激素释放肽增加食物摄入量，减少能量消耗。 然而，尚未进行人体研究来测试生长素释放肽拮抗剂是否具有相反的作用，即是否会减少食物摄入。本研究旨在评价Ghrelin拮抗剂在降低食欲、肥胖和改善胰岛素敏感性方面的作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Obesity represents a major risk factor for diseases such as type 2 diabetes, cardiovascular disease and certain types of cancer. The hypothalamus in the brain is the central regulator of food intake and thus is a key target for anti-obesity drugs. Ghrelin is a peripheral hormone that acts on hypothalamic neurons to increase food intake. Human studies have shown that infusing ghrelin increases food intake and decreases energy expenditure. However, no human studies have been undertaken to test whether a ghrelin antagonist will have the opposite effects i.e. will decrease food intake. This proposal will evaluate the effectiveness of ghrelin antagonist in decreasing appetite and adiposity and improving insulin sensitivity.